Lifileucel TIL therapy (Amtagvi, melanoma 3L+)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-LIFILEUCEL-TIL-MELANOMA |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-C14401-CHESNEY-2024 SRC-NCCN-MELANOMA-2025 |
Notes
C-144-01 pooled cohorts (n=153): ORR 31.4%, mDoR not reached at 27.6 mo follow-up, mOS 13.9 mo — first cellular therapy approved for any solid tumor (FDA 2024-02-16, Iovance Amtagvi). Single- infusion treatment intent (no maintenance). Treatment-related mortality ~7% — patient selection critical: ECOG ≤1, organ function adequate for IL-2 (LVEF ≥45, FEV1 ≥60, DLCO ≥60), no active infection, no chronic immunosuppression. CRITICAL: must AVOID systemic corticosteroids before and shortly after TIL infusion (abrogate TIL function). Specialty-center authorization + REMS-style accreditation required. Ukraine pathway: international referral only.
Used By
Indication
IND-MELANOMA-3L-LIFILEUCEL- IND-MELANOMA-3L-LIFILEUCEL